Ratings by BofA Securities (Sachin Jain)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/25/2025 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 11/25/2025 | Novartis | NVS | Upgrade | Buy (Neutral) |
127.31 (159.90) |
25.6% | Details | |
| 10/2/2024 | Novo Nordisk | NVO | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 5/3/2024 | Novo Nordisk | NVO | Maintain | Buy (N/A) |
|
Details | ||
| 9/5/2023 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 6/6/2022 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2022 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2021 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 10/12/2021 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2021 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2021 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details |
